Hospital Outpatient Reimbursement Increased for 2011
- By BSTQ Staff
In August, the Centers for Medicare and Medicaid Services (CMS) proposed to change the reimbursement rate of separately payable, non-pass-through drugs and biologicals, which include most plasma protein therapies, such as intravenous immune globulin, as well as alpha-1 proteinase inhibitors and blood clotting factors. The increase from average sales price (ASP) plus 4 percent toASP plus 5 percent paid in 2010 was proposed to be effective on Jan. 1, 2011. However, this is not a permanent change, and CMS can change the reimbursement up or down in 2012. To learn more about this rule, refer to page 46281 of the CMS proposed rule document at edocket.access.gpo.gov/2010/pdf/2010-16448.pdf.